Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Outlook Therapeutics (OTLK) Debt to Equity (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Debt to Equity for 7 consecutive years, with -$0.55 as the latest value for Q2 2025.

  • On a quarterly basis, Debt to Equity changed N/A to -$0.55 in Q2 2025 year-over-year; TTM through Jun 2025 was -$0.55, a N/A change, with the full-year FY2019 number at -$0.42, down 6379.6% from a year prior.
  • Debt to Equity was -$0.55 for Q2 2025 at Outlook Therapeutics, up from -$0.65 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of -$0.55 in Q2 2025 to a low of -$0.65 in Q1 2025.